Last reviewed · How we verify
Shigella flexneri 2a Invaplex 50
At a glance
| Generic name | Shigella flexneri 2a Invaplex 50 |
|---|---|
| Sponsor | U.S. Army Medical Research and Development Command |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR) (PHASE1)
- Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection (PHASE1, PHASE2)
- Invaplex 50 Vaccine Dose-Ranging (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: